Breaking News: EGPA Treatment Approved
December 14, 2017
GlaxoSmithKline has announced that the FDA has approved Nucala (mepolizumab) as the first targeted treatment for eosinophilic granulomatosis with polyangiitis (EGPA), previously known as Churg-Strauss syndrome.